ArticleScientific reports2018
Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Potential protein blood-based biomarkers for cognitive dysfunction in Parkinson's disease: a systematic review and network meta-analysis.Frontiers in aging neuroscience · 2026Pooled it
- Cerebrospinal fluid and blood neurofilament light chain in Parkinson's disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis.Journal of neurology · 2025Pooled it
- Systematic review of differentially abundant proteins in people with Lewy body dementia.Acta neuropsychiatrica · 2025Pooled it
- SIMOA-based analysis of plasma NFL levels in MCI and AD patients: a systematic review and meta-analysis.BMC neurology · 2023Pooled it
- Role of Neurofilament Light Chain as a Potential Biomarker for Alzheimer's Disease: A Correlative Meta-Analysis.Frontiers in aging neuroscience · 2019Pooled it
- Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults.Scientific reports · 2021Trial
- Plasma glial fibrillary acidic protein (GFAP) is a biomarker for central nervous system involvement in infantile-onset Pompe disease.EBioMedicine · 2026Article
- Distinct contributions of cerebrospinal fluid biomarkers to cognitive impairment and neuropsychiatric symptoms in young-onset dementia.Acta neuropsychiatrica · 2025Article
- Biomarkers for Lewy body diseases and other alpha-synucleinopathies in biofluids: current evidence and future directions.Journal of translational medicine · 2025Review
- Structural and diffusion imaging in olfactory-related brain regions in Parkinson's disease: predictors of clinical progression.Scientific reports · 2025Article
- Peripheral Inflammation Is Associated With Greater Neuronal Injury and Lower Episodic Memory Among Late Middle-Aged Adults.Journal of neurochemistry · 2025Article
- APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases.Nature medicine · 2025Article
- Investigating T-cell-derived extracellular vesicles as biomarkers of disease activity, axonal injury, and disability in multiple sclerosis.Clinical and experimental immunology · 2025Article
- Association of plasma biomarkers of Alzheimer's pathology and neurodegeneration with gait performance in older adults.Communications medicine · 2025Article
- Neurofilament light chain (Nf-L) in cerebrospinal fluid and serum as a potential biomarker in the differential diagnosis of neurological diseases in cattle.Veterinary research · 2025Article
- Evaluating the safety and feasibility of remote ischemic conditioning for slowing cognitive decline in mild Alzheimer's dementia.Frontiers in neurology · 2025Article
- Efficacy of acupuncture for Parkinson's disease with mild cognitive impairment: study protocol for a randomized controlled trial.Frontiers in neurology · 2025Article
- Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson's disease.Frontiers in neurology · 2025Review
- Cross-cultural validation of plasma p-tau217 and p-tau181 as precision biomarkers for amyloid PET positivity: An East Asian study in Taiwan and Korea.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis.Nature reviews. Neurology · 2024Review
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma neurofilament light (NFL) has been proposed as a blood-based biomarker for neurodegeneration in Alzheimer's disease (AD) and parkinsonian disorders. However, the relationship between plasma NFL and cognitive decline in dementia due to Parkinson's disease (PD) remains to be elucidated. In this research, 119 AD, 56 mild cognitive impairment (MCI), 26 non-demented PD (PDND), and 23 Parkinson's disease dementia (PDD) patients, as well as 59 cognitively healthy controls (HC) were recruited. Each subject underwent a battery of neuropsychological testing. Plasma NFL levels were measured in duplicate using an NF-Light assay and transferred onto the Simoa platform with a home-brew kit. Plasma NFL was significantly increased in the AD group, compared with the control, MCI, PDND, and PDD groups. Plasma NFL was significantly higher in the PDD group, compared with the PDND group. High plasma NFL correlated with poor cognition in AD and PD, but not with motor symptoms in PD. Plasma NFL may represent a biomarker of cognitive decline in AD and PD, with more specificity for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.